about
Characterization of a new chronic lymphocytic leukemia cell line for mechanistic in vitro and in vivo studies relevant to diseaseCD47 agonist peptides induce programmed cell death in refractory chronic lymphocytic leukemia B cells via PLCγ1 activation: evidence from mice and humansAsymmetry of VANGL2 in migrating lymphocytes as a tool to monitor activity of the mammalian WNT/planar cell polarity pathway.Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapyThe MEC1 and MEC2 lines represent two CLL subclones in different stages of progression towards prolymphocytic leukemia.In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor.A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease.Establishment and characterization of PCL12, a novel CD5+ chronic lymphocytic leukaemia cell lineTargeted tumor imaging of anti-CD20-polymeric nanoparticles developed for the diagnosis of B-cell malignancies.Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblastsT-cell number and subtype influence the disease course of primary chronic lymphocytic leukaemia xenografts in alymphoid mice.Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation.Targeting HSF1 disrupts HSP90 chaperone function in chronic lymphocytic leukemia.Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications.Preclinical modeling of novel therapeutics in chronic lymphocytic leukemia: the tools of the tradeAntibody-based therapeutics for the treatment of human B cell malignanciesHIF-1α regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironmentInhibition of chronic lymphocytic leukemia progression by full-length chromogranin A and its N-terminal fragment in mouse models.New advances in leukaemia immunotherapy by the use of Chimeric Artificial Antigen Receptors (CARs): state of the art and perspectives for the near future.Xenograft models of chronic lymphocytic leukemia: problems, pitfalls and future directions.The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia.NOD/SCID IL2Rγ-null mouse xenograft model of human p53-mutated chronic lymphocytic leukemia and ATM-mutated mantle cell lymphoma using permanent cell lines.A combination of an anti-SLAMF6 antibody and ibrutinib efficiently abrogates expansion of chronic lymphocytic leukemia cellsDynamic changes in clonal cytogenetic architecture during progression of chronic lymphocytic leukemia in patients and patient-derived murine xenografts.Actinomycin D induces p53-independent cell death and prolongs survival in high-risk chronic lymphocytic leukemiaHow the microenvironment shapes chronic lymphocytic leukemia: the cytoskeleton connection
P2860
Q27304652-EA5700D5-0CA2-4FD7-AA66-14E39388E130Q28543785-2941469F-CF4A-46CB-BBF0-56EC205B2748Q30619502-D0521531-ED0E-45CE-AC21-D9A51EFF5CAAQ34020276-98596463-376A-457D-975E-26AB0C554943Q34097631-A6B549BD-CF82-40E6-B33C-EC54F4F04939Q35001579-6E35B038-E966-4D3A-8F7F-0FFC5888DA7BQ35029969-2FC825E4-5C35-4CE5-9DFC-BF514E26ADF2Q35674334-EE240C71-F6EF-47A5-930E-B8FEBB8219EEQ35787096-E1BFB05A-FA9B-408F-9EB6-C563C341CC10Q36028740-20756958-3ED9-4957-A692-347CE0FA78ABQ36245171-61D7942D-9655-4581-A307-D8600298E34BQ36515159-EEB2CEBF-2342-4316-8E4C-1B69AEC69F68Q36544683-E33866CE-EEB3-487B-8EE8-8016B72F40EFQ36862781-0458DE72-006E-4B02-BDAD-4F6EADDDBE52Q36867755-84F29A14-7ABE-45E2-8A20-CBFC560DF28EQ36907540-2644AEED-45D8-48EA-9660-5FC5BAA9F8CAQ37097867-8707F32F-7A91-4F36-BB41-E4EF83017CDCQ37520340-8B6A4CA8-416F-4A0B-9378-83446E13B8E3Q37937083-B210D096-4814-4D53-84C6-FB214CCF463EQ38049970-30A1E3AF-654B-4DC1-8929-381DBC03EBA5Q38745915-C5544CFE-7A38-4CD9-8A0D-2E8F4BD76F02Q38892495-E095640D-222D-4BBC-8AF4-7EE1147E3684Q39877099-CBFBD94A-F768-4D2B-B47C-4D1BF71C34D7Q41280348-D0359B15-6CB3-4907-B5D0-B60E08CFB252Q57229768-5CDA3A66-8E8B-4AD4-B49F-CF2D20D839E7Q58042009-45CFD1BC-5607-42AA-8A2F-E92108710CAA
P2860
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
A novel Rag2-/-gammac-/--xenograft model of human CLL.
@en
A novel Rag2-/-gammac-/--xenograft model of human CLL.
@nl
type
label
A novel Rag2-/-gammac-/--xenograft model of human CLL.
@en
A novel Rag2-/-gammac-/--xenograft model of human CLL.
@nl
prefLabel
A novel Rag2-/-gammac-/--xenograft model of human CLL.
@en
A novel Rag2-/-gammac-/--xenograft model of human CLL.
@nl
P2093
P50
P1433
P1476
A novel Rag2-/-gammac-/--xenograft model of human CLL.
@en
P2093
Benedetta Apollonio
Claudia Fazi
Federico Caligaris-Cappio
Lydia Scarfò
Maria Teresa Sabrina Bertilaccio
Martina Rocchi
Maurilio Ponzoni
P304
P356
10.1182/BLOOD-2009-05-223586
P407
P577
2009-12-16T00:00:00Z